Table Graph
   

inhaled interferon - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 2.45 [0.21, 28.37]< 10%2 studies (2/-)23.8 %some concernnot evaluable moderatecrucial-
deaths 0.80 [0.40, 1.59]< 10%4 studies (4/-)74.2 %NAnot evaluable crucial-
clinical deterioration 0.65 [0.42, 1.00]< 10%2 studies (2/-)97.4 %NAnot evaluable important-
clinical improvement 1.36 [0.41, 4.50]> 166%2 studies (2/-)69.4 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.03 [0.17, 24.32]> 175%2 studies (2/-)71.0 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.15 [1.39, 7.14]> 10%1 study (1/-)99.7 %NAnot evaluable important-
clinical improvement (7-day) 1.91 [1.03, 3.53]> 10%1 study (1/-)98.0 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.02 [0.81, 1.28]> 10%1 study (1/-)56.7 %NAnot evaluable important-
death or ventilation 0.75 [0.42, 1.34]< 10%2 studies (2/-)83.7 %NAnot evaluable important-
hospital discharge 1.07 [0.90, 1.28]> 10%2 studies (2/-)79.0 %NAnot evaluable important-
Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 10%1 study (1/-)56.7 %NAnot evaluable important-
viral clearance 2.69 [1.48, 4.87]> 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.18 [0.00, 435.69]> 198%2 studies (2/-)34.4 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.69 [1.48, 4.87]> 10%2 studies (2/-)99.9 %some concernnot evaluable moderateimportant-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.95 [0.02, 50.33]< 10%1 study (1/-)51.0 %NAnot evaluable important-
adverse events 1.68 [0.47, 5.97]< 10%1 study (1/-)21.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons